



health

Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. DR AB Xuma Building, 1112 Voortrekker Road, Pretoria Townlands 351-JR, PRETORIA 0187
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: tenders@health.gov.za

Ref: **HP04-2022ONC**

**HP04-2022ONC: SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE
DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO 30 JUNE 2024**

1. The attached contract circular is for your information.
2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.
3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.
4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape	Mr D Martin	(041) 406-9815	deon.martin@echealth.gov.za
Free State	Ms M Smits	(051) 411-0525	smitsm@fshealth.gov.za
Gauteng	Ms P Nyokong	(011) 628-9011	pretty.nyokong@gauteng.gov.za
Kwazulu-Natal	Ms T Njapha	(031) 469-8300	Thandeka.Njapha@kznhealth.gov.za
Limpopo	Mr TS Rasekele	(015) 223-9065	rassolly@gmail.com
Mpumalanga	Ms M Moloto	(013) 283-9001	MargaretMm@mpuhealth.gov.za
North-West	Ms Z Maqutu	(018) 384-4838	zmaqutu@nwpg.gov.za
Northern Cape	Ms E Delport	(053) 830-2717	edelport@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
For: DIRECTOR-GENERAL: HEALTH
DATE: 22 April 2022

(PAGE 2)

1. IMPORTANT GENERAL INFORMATION

- 1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.
- 1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.
- 1.3 All prices are inclusive of 15 % VAT.
- 1.4 All prices are on a delivered basis.
- 1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Accord Healthcare (Pty) Ltd	V2MB8	MAAA0005335	Private Bag X51 Postnet Suite 182 RIVONIA 2128	Shameer Suleman	(011) 234 5703 (083) 778 6902	shameer@accordhealth.co.za
Acino Pharma (Pty) Ltd	VGS73	MAAA0009244	P O Box 8374 MIDRAND 1685	Anand Reddy	(011) 516 1700 (066) 304 6900	state_za@acino.swiss
Ascend Laboratories (Pty) Ltd	VQ9W1	MAAA1120849	P O Box 6646 BAILLIE PARK 2526	Mervin Naidoo	(083) 789 8418	mervin.naidoo@imperiallogistics.com
AstraZeneca Pharmaceuticals (Pty) Ltd	V2180	MAAA0006577	Private Bag X23 BRAYNSTON 2021	Phumlani Mancapha	(011) 797 6000 (084) 468 2420	phumlani.mancapha1@astrazeneca.com

(PAGE 3)

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Baxter Healthcare SA (Pty) Ltd	V3KX0	MAAA0153863	P O Box 70562 BRYANSTON 2021	Terri Myburgh	(011) 790 2000 (082) 657 1849	terri_myburgh@baxter.com
Bayer (Pty) Ltd	V6390	MAAA0009623	P O Box 143 ISANDO 1600	Magda Noack	(011) 921 5279	za_tenders@bayer.com
Biotech Laboratories (Pty) Ltd	VUV35	MAAA0029826	Suite 150 Private Bag X65 HALFWAY HOUSE 1685	Faried Dean	(011) 848 3050 (082) 455 1149	tenders@biotechlabs.co.za
Cipla Medpro SA (Pty) Ltd t/a Cipla Medpro Manufacturing	VXZ32	MAAA0006605	P O Box 32003 MOBENI 4060	Willem Maritz	(011) 315 9150 (082) 887 4926	willem.maritz@cipla.com
Fresenius Kabi SA (Pty) Ltd	VAJL3	MAAA0007374	P O Box 4156 HALFWAY HOUSE 1685	Jeannine Terblanche	(011) 545 0000	jeannine.terblanche@fresenius-kabi.com
Hetero Drugs SA (Pty) Ltd	VB2N1	MAAA0323938	Waterfall Corporate Campus, Building 2, First Floor 74 Waterfall Drive, Waterfall City MIDRAND 2066	Nahum Johnson	(012) 644 1220 (082) 388 7226	johnson.n@heterodrugs.com
Key Oncologics (Pty) Ltd	VAYM6	MAAA0009144	Postnet Suite 19 P O Box 92418 NORWOOD 2117	Margaretha De Wet	(011) 483 0060 (082) 567 5197	magriet@keyoncologics.co.za

(PAGE 4)

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Medivision (Pty) Ltd	V20D5	MAAA0002347	P O Box 178 ISANDO 1600	Vibha Desai	(010) 492 3809 (083) 236 7123	vibha@avakash.net
Merck (Pty) Ltd	V3018	MAAA0022370	P O Box 1998 HALFWAY HOUSE 1685	Herman Burger	(011) 372 5085 (083) 579 0653	herman.burger@merckgroup.com
Novartis SA (Pty) Ltd	VBVW2	MAAA0006317	P O Box 12253 VORNA VALLEY 1686	Christy Maduray	(011) 347 6600 (076) 015 5995	christy.maduray@novartis.com
Oethmaan Biosims (Pty) Ltd.	V91P2	MAAA0437774	P O Box 421001 FORDSBURG 2033	Muhammad Bodhanian	(011) 433 0602 (083) 325 3741	mbodhanian@medreich.co.za
Pfizer Laboratories (Pty) Ltd	V2189	MAAA0019202	P O Box 783720 SANDTON 2146	Themba Mnguni	(011) 320 6091 (082) 307 9658	themba.mnguni@pfizer.com
Pharmacare Limited	V2205	MAAA0008452	P O Box 1593 GALLO MANOR 2052	Itumeleng Mathe	(011) 239 6243 (083) 298 4336	imathe@aspenpharma.com
Pharmaco Distribution (Pty) Ltd	VBVW1	MAAA0044115	P O Box 786522 SANDTON 2146	Jay Raaff	(011) 784 0077 (082) 555 6519	jay.raaff@pharmaco.co.za
Ranbaxy Pharmaceuticals (Pty) Ltd	V4728	MAAA0000384	P O Box 43486 INDUSTRIA 2042	Deepakh Mangal Sewnarain	(012) 643 2000 (082) 893 8649	deepakh.sewnarain@sunpharma.com
Roche Products (Pty) Ltd	V2177	MAAA0007487	P O Box 1469 HALFWAY HOUSE 1685	Dr Kgothatso Motumi	(011) 504 4729 (076) 510 9334	kgothatso.motumi@roche.com

(PAGE 5)

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Sandoz SA (Pty) Ltd	VVZ69	MAAA0011663	P O Box 12257 VORNA VALLEY 1686	Renee Moodley	(011) 545 0424 (083) 704 1806	renee.moodley@sandoz.com
Sanofi-Aventis SA (Pty) Ltd	V2160	MAAA0009069	Private Bag X207 MIDRAND 1685	Jaidev Maharaj	(011) 847 5264 (082) 943 3952	jaidev.maharaj@sanofi.com
Teva Pharmaceuticals (Pty) Ltd	V43G1	MAAA0842904	Teva Pharmaceuticals (Pty) Ltd P O Box 1590 RUIMSIG 1732	Judy Klinkradt	(011) 055-0200 (082) 771 3513	judy.klinkradt@teva.co.za

TO THE DEPARTMENT OF HEALTH

Item No	Item Specification	Therapeutic Class Number	UNIT	Quantity Awarded	Supplier Name	Delivered Price as per Unit	Offered Unit Pack Size Price (if applicable)	Registered Product Name	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
1	Anastrozole 1mg tablet, 28 tablets	Class 4	Pack of 28 tablets	115 239	Medivision (Pty) Ltd	R25.85	n/a	Medivision Anastrozole 1	1 x 28 tablets	14	30	100.00	222001259	CO
5	Azathioprine 50mg tablet, 100 tablets		Pack of 100 tablets	91 743	Acino Pharma (Pty) Ltd	R102.35	n/a	Azamun 50mg Tablets	1 x 100 tablets	14	50	100.00	189710268	CO
6	Bevacizumab 100mg injection		Each	4 780	Roche Products (Pty) Ltd	R2 668.00	n/a	Avastin Injection 100mg/4ml	1 x 1 vial	14	1 vial	90.00	181817552	VI
8	Bortezomib 3.5mg injection, 10ml		Each	720	Accord Healthcare (Pty) Ltd	R592.25	n/a	Valtib 3,5mg	1 x 1 vial	14	20	91.00	181816794	VI
10	Busulfan 2mg tablet, 100 tablets		Pack of 100 tablets	264	Pharmacare Limited	R1 248.68	n/a	MYLERAN 2MG TAB 100	1 x 100 tablets	14	1	90.00	189710642	CO
11	Calcium Folate equivalent to Folinic Acid 15mg tablet, 10 tablets		Pack of 10 tablets	4 007	Teva Pharmaceuticals (Pty) Ltd	R252.15	n/a	RESCUVOLIN 15MG	1 x 10 tablets	14	10	90.00	189711671	CO
12	Calcium Folate, equivalent to Folinic Acid, 100mg injection		Each	12 950	Teva Pharmaceuticals (Pty) Ltd	R229.93	n/a	ABIC LEUCOVORIN 100MG/10ML INJECTION	1 x 1 vial	14	10	90.00	222001016	VI
13	Calcium Folate, equivalent to Folinic Acid, 300mg injection		Each	1 502	Teva Pharmaceuticals (Pty) Ltd	R689.86	n/a	ABIC LEUCOVORIN 300MG/30ML INJECTION	1 x 1 vial	14	5	90.00	181848888	VI
14	Capecitabine 150mg tablet, 60 tablets Items 14 and 15 will be considered as a series	Series 1	Pack of 60 tablets	13 974	Accord Healthcare (Pty) Ltd	R138.00	n/a	Capexa 150mg	1 x 60 tablets	14	20	91.00	180957667	CO
15	Capecitabine 500mg tablet, 120 tablets Items 14 and 15 will be considered as a series	Series 1	Pack of 120 tablets	19 868	Accord Healthcare (Pty) Ltd	R736.00	n/a	Capexa 500mg	1 x 120 tablets	14	20		180958744	CO
16	Carboplatin 150mg injection Items 16 and 17 will be considered as a series	Series 2	Each	8 580	Accord Healthcare (Pty) Ltd	R174.80	n/a	Accord-Carboplatin 10mg/15ml	1 x 15ml vial	14	20	91.00	189714187	VI
17	Carboplatin 450mg injection Items 16 and 17 will be considered as a series	Series 2	Each	32 711	Accord Healthcare (Pty) Ltd	R391.00	n/a	Accord-Carboplatin 10mg/45ml	1 x 45ml vial	14	20		181744809	VI
18	Chlorambucil 2mg tablet, 25 tablets		Pack of 25 tablets	4 316	Pharmacare Limited	R432.02	n/a	LEUKERAN 2MG TABS 25'S	1 x 25 tablets	14	3	90.00	189710834	CO
19	Ciclosporin 100mg capsule, 50 capsules Items 19 and 21 will be considered as a series	Series 3	Pack of 50 capsules	19 154	Novartis SA (Pty) Ltd	R798.77	n/a	SANDIMMUN NEORAL CAPS 100MG	1 x 50 capsules	14	1	92.00	180001233	CO
20	Ciclosporin 100mg/ml oral solution, 50ml		Each	497	Novartis SA (Pty) Ltd	R955.02	n/a	SANDIMMUN NEORAL DRINK SOL 100MG/ML	1 x 1 vial	14	1	92.00	189712364	VI
21	Ciclosporin 25mg capsule, 50 capsules Items 19 and 21 will be considered as a series	Series 3	Pack of 50 capsules	37 323	Novartis SA (Pty) Ltd	R199.85	n/a	SANDIMMUN NEORAL CAPS 25mg	1 x 50 capsules	14	1	92.00	180001218	CO
22	Ciclosporin 50mg injection		Each	14 940	Novartis SA (Pty) Ltd	R63.99	R639.98	SANDIMMUN AMPS 50mg/ml 10	1 x 10 ampoules	14	1	92.00	180073825	AM
23	Cisplatin 10mg injection Items 23 and 24 will be considered as a series	Series 4	Each	6 660	Oethmaan Biosims (Pty) Ltd	R42.49	n/a	Cisplatin 10mg/ 20ml Oethmaan	1 x 1 vial	14	20	100.00	180348859	VI
24	Cisplatin 50mg injection Items 23 and 24 will be considered as a series	Series 4	Each	67 800	Oethmaan Biosims (Pty) Ltd	R108.04	n/a	Cisplatin 50mg / 100ml Oethmaan	1 x 1 vial	14	20		180348860	VI
25	Cyclophosphamide 1g injection Items 25 and 26 will be considered as a series	Series 5	Each	55 406	Baxter Healthcare SA (Pty) Ltd	R132.85	n/a	Endoxan 1g Injection	1 x 1 vial	14	1	91.00	189704487	VI
26	Cyclophosphamide 500mg injection Items 25 and 26 will be considered as a series	Series 5	Each	8 686	Baxter Healthcare SA (Pty) Ltd	R90.57	n/a	Endoxan 500mg Injection	1 x 1 vial	14	1		189714915	VI
27	Cyclophosphamide 50mg tablet, 50 tablets		Pack of 50 tablets	5 927	Baxter Healthcare SA (Pty) Ltd	R221.01	n/a	Endoxan 50mg Tablets, 50s	1 x 50 tablets	14	1	91.00	189714585	CO
30	Dacarbazine 200mg injection		Each	32 530	Key Oncologics (Pty) Ltd	R698.87	R6 988.70	Dacin 200 mg	1 x 10 vials	2	1 pack	90.00	180073563	VI
32	Docetaxel 20mg injection Items 32 and 33 will be considered as a series	Series 7	Each	6 662	Sandoz SA (Pty) Ltd	R295.00	n/a	Prosaglic 20mg/2ml	1 x 1 vial	14	10	91.00	180182958	VI
33	Docetaxel 80mg injection Items 32 and 33 will be considered as a series	Series 7	Each	31 736	Sandoz SA (Pty) Ltd	R370.00	n/a	Prosaglic 80mg/8ml	1 x 1 vial	14	10		180182961	VI
34	Doxorubicin 10mg injection Items 34 and 35 will be considered as a series	Series 8	Each	18 972	Oethmaan Biosims (Pty) Ltd	R70.67	n/a	HX-Doxorubicin 10mg / 5ml	1 x 1 vial	14	20	100.00	189762107	VI

TO THE DEPARTMENT OF HEALTH

Item No	Item Specification	Therapeutic Class Number	UNIT	Quantity Awarded	Supplier Name	Delivered Price as per Unit	Offered Unit Pack Size Price (if applicable)	Registered Product Name	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
35	Doxorubicin 50mg injection Items 34 and 35 will be considered as a series	Series 8	Each	98 468	Oethmaan Biosims (Pty) Ltd	R163.88	n/a	HX-Doxorubicin 50mg / 25ml	1 x 1 vial	14	10		189762108	VI
36	Epirubicin 10mg injection Items 36 and 37 will be considered as a series	Series 9	Each	2 372	Accord Healthcare (Pty) Ltd	R127.65	n/a	Accord Epirubicin 10mg	1 x 5ml vial	14	20	91.00	189710736	VI
37	Epirubicin 50mg injection Items 36 and 37 will be considered as a series	Series 9	Each	42 814	Accord Healthcare (Pty) Ltd	R307.05	n/a	Accord Epirubicin 50mg	1 x 25ml vial	14	20		189710735	VI
38	Etoposide 100mg injection		Each	47 292	Teva Pharmaceuticals (Pty) Ltd	R141.54	n/a	EPOSIN	1 x 1 vial	14	15	90.00	180076160	VI
39	Everolimus 0.25mg tablet, 60 tablets Items 39 and 40 will be considered as a series	Series 10	Pack of 60 tablets	1 020	Novartis SA (Pty) Ltd	R640.00	n/a	CERTICAN TABS 0.25MG	1 x 60 tablets	14	1	92.00	181807552	CO
40	Everolimus 0.75mg tablet, 60 tablets Items 39 and 40 will be considered as a series	Series 10	Pack of 60 tablets	1 290	Novartis SA (Pty) Ltd	R1 919.93	n/a	CERTICAN TABS 0.75MG	1 x 60 tablets	14	1		181810492	CO
41	Exemestane 25mg tablet, 28 tablets		Pack of 28 tablets	5 180	Pfizer Laboratories (Pty) Ltd	R186.13	n/a	AROMASIN 25MG	1 x 30 tablets	14	1	92.00	181785231	CO
42	Filgrastim 30MU prefilled syringe		Each	85 648	Teva Pharmaceuticals (Pty) Ltd	R327.70	R1 638.50	FILGRASTIM TEVA 30	1 x 5 syringes	14	5	90.00	181747103	SG
43	Filgrastim 48MU prefilled syringe		Each	6 884	Teva Pharmaceuticals (Pty) Ltd	R506.58	R2 532.90	FILGRASTIM TEVA 48	1 x 5 syringes	14	5	90.00	180954695	SG
44	Fludarabine 10mg tablet, 20 tablets		Pack of 20 tablets	544	Sanofi-Aventis SA (Pty) Ltd	R8 722.27	n/a	FLUDARA 10MG ORAL TABS 20	1 x 20 tablets	14	1	92.00	181840965	CO
45	Fludarabine Phosphate 50mg injection		Each	2 548	Teva Pharmaceuticals (Pty) Ltd	R363.08	n/a	TEVA FLUDARABINE 50	1 x 1 vial	14	5	90.00	180221925	VI
50	Gemcitabine 1g injection Items 50 and 51 will be considered as a series	Series 11	Each	25 754	Oethmaan Biosims (Pty) Ltd	R210.45	n/a	Hexal Gemcitabine 1g IVI	1 x 1 vial	14	20	100.00	180188832	VI
51	Gemcitabine 200mg injection Items 50 and 51 will be considered as a series	Series 11	Each	2 664	Oethmaan Biosims (Pty) Ltd	R93.32	n/a	Hexal Gemcitabine 200mg IVI	1 x 1 vial	14	20		180188801	VI
52	Goserelin 10.8mg injection	Class 1	Each	61 110	AstraZeneca Pharmaceuticals (Pty) Ltd	R816.50	n/a	Zoladex 10.8mg	1 x 1 syringe	10	10	91.00	180969540	SG
53	Goserelin 3.6mg injection		Each	7 772	AstraZeneca Pharmaceuticals (Pty) Ltd	R483.00	n/a	Zoladex 3.6mg	1 x 1 syringe	10	10	91.00	189709944	SG
54	Granisetron 1mg injection		Each	65 620	Fresenius Kabi SA (Pty) Ltd	R8.20	n/a	Granisetron Fresenius 1 mg/ml (1 ml)	1 x 1 ampoule	14	5	90.00	180968745	AM
56	Granisetron 3mg injection		Each	29 116	Fresenius Kabi SA (Pty) Ltd	R15.48	n/a	Granisetron Fresenius 1 mg/ml (3 ml)	1 x 1 ampoule	14	5	90.00	180073795	AM
58	Ibandronic acid 6mg injection	Class 3	Each	18 417	Accord Healthcare (Pty) Ltd	R126.50	n/a	BONRIX 6 mg/6 ml	1 x 6ml vial	14	1 x 6 vials	91.00	222000026	EA
60	Ifosfamide 1g injection Items 60, 61 and 62 will be considered as a series	Series 12	Each	7 706	Baxter Healthcare SA (Pty) Ltd	R567.23	n/a	Holoxan 1g Injection	1 x 1 vial	14	1	91.00	189714258	VI
61	Ifosfamide 2g injection Items 60, 61 and 62 will be considered as a series	Series 12	Each	11 554	Baxter Healthcare SA (Pty) Ltd	R916.53	n/a	Holoxan 2g injection	1 x 1 vial	14	1		189714259	VI
62	Ifosfamide 500mg injection Items 60, 61 and 62 will be considered as a series	Series 12	Each	540	Baxter Healthcare SA (Pty) Ltd	R340.34	n/a	Holoxan 500mg injection	1 x 1 vial	14	1		189714257	VI
63	Imatinib 100mg tablet/capsule, 60 tablets/capsules		Pack of 60 tablets/capsules	13 598	Accord Healthcare (Pty) Ltd	R115.00	n/a	Imatinib Accord 100mg	1 x 60 tablets	14	20	91.00	181758086	CO
64	Imatinib 400mg tablet/capsule, 30 tablets/capsules		Pack of 30 tablets/capsules	12 995	Accord Healthcare (Pty) Ltd	R287.50	n/a	Imatinib Accord 400mg	1 x 30 tablets	14	20	91.00	181823721	CO
65	Interferon Beta-1a Injection containing 6M IU per ml after reconstitution, injection		Each	458	Merck (Pty) Ltd	R410.47	R4 925.66	Rebif 44	1 x 12 vials	6	1 x 12	90.00	181810858	VI
66	Interferon Beta-1b, 8M IU per ml after reconstitution, injection		Each	17 005	Bayer (Pty) Ltd	R272.86	R4 092.90	Betaferon	1 x 15 vials	14	15	90.00	222001070	VI
67	Irinotecan 100mg injection		Each	11 540	Oethmaan Biosims (Pty) Ltd	R169.05	n/a	Irinotecan 100 Oethmaan	1 x 1 vial	14	20	95.50	180281234	VI

TO THE DEPARTMENT OF HEALTH

Item No	Item Specification	Therapeutic Class Number	UNIT	Quantity Awarded	Supplier Name	Delivered Price as per Unit	Offered Unit Pack Size Price (if applicable)	Registered Product Name	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
68	Irinotecan 40mg injection		Each	624	Oethmaan Biosims (Pty) Ltd	R96.60	n/a	Irinotecan 40 Oethmaan	1 x 1 vial	14	20	95.50	180347574	VI
70	Letrozole 2.5mg tablet, 28 tablets		Pack of 28 tablets	2 850	Hetero Drugs SA (Pty) Ltd	R29.26	n/a	Letrozole 2.5 mg Hetero	1 x 28 tablets	14	1	94.00	222001260	CO
71	Medroxyprogesterone Acetate 100mg tablet, 100 tablets		Pack of 100 tablets	628	Pfizer Laboratories (Pty) Ltd	R832.83	n/a	PROVERA 100MG	1 x 100 tablets	14	1	92.00	189711677	CO
74	Mercaptopurine 50mg tablet, 25 tablets		Pack of 25 tablets	11 384	Pharmacare Limited	R1 118.86	n/a	PURINETHOL 50MG TABS 25'S	1 x 25 tablets	14	1	90.00	189710669	CO
75	Mesna 400mg injection		Each	80 684	Baxter Healthcare SA (Pty) Ltd	R42.04	R630.60	Urometixan 400mg injection, 15amp	1 x 15 ampoules	14	1 x 15	91.00	189711688	AM
76	Methotrexate 1g injection		Each	11 112	Teva Pharmaceuticals (Pty) Ltd	R574.04	n/a	ABITREXATE 1G	1 x 1 vial	14	5	90.00	189715286	VI
77	Methotrexate 2.5mg tablet, 100 tablets		Pack of 100 tablets	152 981	Teva Pharmaceuticals (Pty) Ltd	R157.26	n/a	ABITREXATE 2,5 mg TABLETS	1 x 100 tablets	14	15	90.00	189752693	CO
78	Methotrexate 50mg injection		Each	21 224	Teva Pharmaceuticals (Pty) Ltd	R44.34	n/a	ABITREXATE 50	1 x 1 vial	14	45	90.00	181767289	VI
79	Methotrexate 5g injection		Each	1 640	Teva Pharmaceuticals (Pty) Ltd	R3 182.46	n/a	ABITREXATE 5 g	1 x 1 vial	14	1	90.00	189714911	VI
81	Mycophenolate mofetil 200mg/ml suspension, 175ml		Each	81	Roche Products (Pty) Ltd	R1 624.58	n/a	Cellcept Oral Susp 200mg/ml 5ml	1 x 175ml bottle	14	1	90.00	181932695	BT
82	Mycophenolate mofetil 250mg capsule, 100 capsules Items 82 and 83 will be considered as a series	Series 13	Pack of 100 capsules	37 999	Ascend Laboratories (Pty) Ltd	R169.00	n/a	Mycokem 250	1 x 100 capsules	14	1	92.00	180300085	CO
83	Mycophenolate mofetil 500mg tablet, 50 tablets Items 82 and 83 will be considered as a series	Series 13	Pack of 50 tablets	58 988	Ascend Laboratories (Pty) Ltd	R169.00	n/a	Mycokem 500	1 x 50 tablets	14	1		181820031	CO
84	Mycophenolic acid 180mg tablet, 120 tablets Items 84 and 85 will be considered as a series	Series 14	Pack of 120 tablets	1 290	Novartis SA (Pty) Ltd	R847.08	n/a	MYFORTIC FCT 180MG	1 x 120 tablets	14	1		181835259	CO
85	Mycophenolic acid 360mg tablet, 120 tablets Items 84 and 85 will be considered as a series	Series 14	Pack of 120 tablets	2 317	Novartis SA (Pty) Ltd	R1 140.02	n/a	MYFORTIC FCT 360MG	1 x 120 tablets	14	1		181813273	CO
86	Nilotinib 200mg capsule, 112 capsules		Pack of 112 capsules	4 076	Novartis SA (Pty) Ltd	R2 368.67	n/a	TASIGNA 200MG CAPS	1 x 112 capsules	14	1	92.00	181866360	CO
87	Ondansetron 4mg dispersible tablet, 10 tablets		Pack of 10 tablets	32 470	Ranbaxy Pharmaceuticals (Pty) Ltd	R6.50	n/a	ZOFER RAPITAB 4	1 x 10 tablets	14	10	93.00	180954155	CO
88	Ondansetron 4mg injection		Each	260 796	Biotech Laboratories (Pty) Ltd	R2.35	R11.75	ONDANSETRON 4mg/2ml Biotech	1 x 5 ampoules	14	5	95.00	180073817	AM
89	Ondansetron 8mg injection		Each	313 810	Biotech Laboratories (Pty) Ltd	R4.00	R20.00	ONDANSETRON 8mg/4ml Biotech	1 x 5 ampoules	14	5	95.00	180073819	AM
90	Ondansetron 8mg tablet, 10 tablets	Class 2	Pack of 10 tablets	73 580	Ranbaxy Pharmaceuticals (Pty) Ltd	R6.79	n/a	ZOFER 8mg TABLETS	1 x 10 tablets	14	10	93.00	181858255	CO
91	Oxaliplatin 100mg injection Items 91 and 92 will be considered as a series	Series 15	Each	16 670	Accord Healthcare (Pty) Ltd	R227.70	n/a	Oplaxin 100mg RTU	1 x 20ml vial	14	20	91.00	181804852	VI
92	Oxaliplatin 50mg injection Items 91 and 92 will be considered as a series	Series 15	Each	11 080	Accord Healthcare (Pty) Ltd	R155.25	n/a	Oplaxin 50mg RTU	1 x 10ml vial	14	20		181804849	VI
93	Paclitaxel 100mg injection Items 93, 94 and 108 will be considered as a series	Series 16	Each	58 414	Oethmaan Biosims (Pty) Ltd	R296.47	n/a	Loxat 100	1 x 1 vial	14	8	100.00	180270223	VI
94	Paclitaxel 30mg injection Items 93, 94 and 108 will be considered as a series	Series 16	Each	15 790	Oethmaan Biosims (Pty) Ltd	R110.73	n/a	Loxat 30	1 x 1 vial	14	10		180138165	VI

TO THE DEPARTMENT OF HEALTH

Item No	Item Specification	Therapeutic Class Number	UNIT	Quantity Awarded	Supplier Name	Delivered Price as per Unit	Offered Unit Pack Size Price (if applicable)	Registered Product Name	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	NSN	UOM
96	Rituximab 100mg injection Items 96 and 97 will be considered as a series	Series 17	Each	14 202	Roche Products (Pty) Ltd	R993.70	R1 987.40	Mabthera Vials 100mg 2	1 x 2 10ml vials	14	2	90.00	181752974	VI
97	Rituximab 500mg injection Items 96 and 97 will be considered as a series	Series 17	Each	7 856	Roche Products (Pty) Ltd	R7 618.75	n/a	Mabthera Vials 500mg	1 x 1 50ml vial	14	1		180669542	VI
98	Sirolimus 1mg tablet, 30 tablets		Pack of 30 tablets	7 686	Pfizer Laboratories (Pty) Ltd	R2 420.60	n/a	RAPAMUNE 1MG	1 x 30 tablets	14	1	92.00	181756276	CO
99	Tacrolimus 0.5mg capsules, 30 capsules Items 99, 100 and 101 will be considered as a series	Series 18	Pack of 30 capsules	18 290	Accord Healthcare (Pty) Ltd	R91.08	n/a	Tarograf 0.5mg 30's	1 x 30 capsules	14	20	91.00	222000430	CO
100	Tacrolimus 1mg capsule, 30 capsules Items 99, 100 and 101 will be considered as a series	Series 18	Pack of 30 capsules	102 689	Accord Healthcare (Pty) Ltd	R180.78	n/a	Tarograf 1mg 30's	1 x 30 capsules	14	20		222000431	CO
101	Tacrolimus 5mg capsule, 30 capsules Items 99, 100 and 101 will be considered as a series	Series 18	Pack of 30 capsules	12 636	Accord Healthcare (Pty) Ltd	R892.86	n/a	Tarograf 5mg 30's	1 x 30 capsules	14	20		222000432	CO
102	Tamoxifen 20mg tablet, 28 tablets		Pack of 28 tablets	192 985	Teva Pharmaceuticals (Pty) Ltd	R108.79	n/a	TAMOPLEX 20 mg	1 x 28 tablets	14	15	90.00	189714589	CO
103	Teriflunomide 14mg tablets, 28 tablets		Pack of 28 tablets	3 272	Sanofi-Aventis SA (Pty) Ltd	R5 060.00	n/a	AUBAGIO 14MG 28 TABS	1 x 28 tablets	14	1	92.00	222001184	CO
104	Thalidomide 50mg capsule, 28 capsules		Pack of 28 capsules	9 084	Key Oncologics (Pty) Ltd	R1 484.08	n/a	Thalidomide Celgene 50 mg	1 x 28 capsules	2	2	90.00	181809032	CO
105	Thioguanine 40mg tablet, 25 tablets		Pack of 25 tablets	1 300	Pharmacare Limited	R2 395.33	n/a	LANVIS 40MG TABS 25'S	1 x 25 tablets	14	1	90.00	189712247	CO
106	Trastuzumab 440mg injection		Each	4 300	Cipla Medpro SA (Pty) Ltd t/a Cipla Medpro Manufacturing	R3 450.00	n/a	Trastuzumab Cipla 440mg	1 x 1 vial	14	2	96.00	181776294	VI
107	Tretinoin 10mg capsule, 100 capsules		Pack of 100 capsules	1 940	Pharmaco Distribution (Pty) Ltd	R4 370.00	n/a	Vesanoid 10mg Capsules	1 x 100 capsules	14	2	90.00	180187764	CO
108	VENTED INTRAVENOUS GIVING SET FOR PACLITAXEL Must be DEHP free Y-SITE INJECTION TOTAL LENGTH: ABOUT 180-190CM LUER LOCK END GRAVITY FEED ONLY MUST HAVE 0.2 MICRON FILTER, AND PRIMING VOLUME 19-20ML (APPROX) Items 93, 94 and 108 will be considered as a series	Series 16	Each	26 890	Oethmaan Biosims (Pty) Ltd	R20.70	n/a	OB Paclitaxel Injection set	1 x 1 each	14	10	100.00	222001261	EA
111	Vincristine 2mg injection Items 110 and 111 will be considered as a series Note: Vincristine 1mg injection is not awarded	Series 19	Each	32 767	Accord Healthcare (Pty) Ltd	R81.65	n/a	Accord-Vincristine 1mg/ml	1 x 2ml vial	14	20	91.00	189710632	VI



SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP04-2022ONC

**SUPPLY AND DELIVERY OF ONCOLOGY AND IMMUNOLOGICAL AGENTS TO THE
DEPARTMENT OF HEALTH FOR THE PERIOD 01 JULY 2022 TO
30 JUNE 2024**

BID VALIDITY PERIOD: 180 DAYS

CLOSING DATE AND TIME OF BID:

18 OCTOBER 2021 AT 11H00

NON COMPULSORY ONLINE BRIEFING SESSION:

ZOOM WEBINAR: 27 AUGUST 2021 AT 10:00



INDEX

ABBREVIATIONS	4
BID DOCUMENT CHECK LIST	5
SECTION A	8
LEGISLATIVE AND REGULATORY FRAMEWORK	8
BID INFORMATION SESSION	8
EVALUATION CRITERIA	9
PHASE I: MANDATORY REQUIREMENTS	9
LEGISLATIVE REQUIREMENTS TO THIS BID	9
RESPONSIVE BIDS	10
BID DOCUMENTS	10
AUTHORISATION DECLARATION	11
TAX COMPLIANCE STATUS	11
PHASE II: PRODUCT TECHNICAL COMPLIANCE	13
SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS	13
COMPLIANCE WITH SPECIFICATIONS	14
PHASE IV: PREFERENCE POINT SYSTEM	14
A MAXIMUM OF 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS	14
POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR	15
PREFERENCE FOR LOCALLY PRODUCED PRODUCTS	16
VALUE ADDED TAX	17
SUBMISSION OF BIDS	17
COMPLETION OF DOCUMENTS AND BID SUBMISSION	19
LATE BIDS	20
COUNTER CONDITIONS	20
FRONTING	20
SUPPLIER DUE DILIGENCE	21
COMMUNICATION	21
CONTACT DETAILS	22
SECTION B	23
CONTRACT PERIOD	23
PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS	23
REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES	23
POST AWARD PARTICIPATION	24
AWARD CONDITIONS	24
SPLIT AND MULTIPLE AWARDS	25
THERAPEUTIC CLASS AWARDS	25
NEGOTIATIONS	27
NON-COMMITMENT	27
PRICE REVIEW	27
ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS	27



INSTRUCTIONS FOR PRICE BREAKDOWN	27
PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK	28
APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS	29
ROUTINE PRICE ADJUSTMENTS	29
EXCEPTIONAL PRICE ADJUSTMENTS	29
PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW	30
QUALITY	31
DELIVERY AND QUANTITIES	31
DELIVERY BASIS	31
QUANTITIES	31
SECTION C	32
SUPPLIER PERFORMANCE MANAGEMENT	32
DELIVERY ADHERENCE	33
CONTINUITY OF SUPPLY	34
REPORTING	35
PACKAGING, LABELLING AND BARCODES	36
PACKAGING	36
LABELLING	36
BARCODES	37
SHELF LIFE	38
ACQUISITIONS, CEDING, MERGERS, TAKE OVERS, AND NAME CHANGES	38
CANCELLATION OF THE CONTRACT	39
THIRD PARTIES	39



ABBREVIATIONS

API	: Active Pharmaceutical Ingredient
BAC	: Bid Adjudication Committee
B-BBEE	: Broad-Based Black Economic Empowerment
CPA	: Contract Price Adjustment
CSD	: Central Supplier Database
EAN	: European Article Numbering
EME	: Exempted Micro Enterprise
GMP	: Good Manufacturing Practice
MCC	: Medicines Control Council
MHPL	: Master Health Products List
MPC	: Master Procurement Catalogue
NDoH	: National Department of Health
PPPFA	: Preferential Procurement Policy Framework Act
QSE	: Qualifying Small Enterprise
RoE	: Rate of Exchange
SAHPRA	: South African Health Products Regulatory Authority
SARS	: South African Revenue Service
SBD	: Standard Bidding Document
VAT	: Value- Added Tax



BID DOCUMENT CHECK LIST

All bid documents listed below must be sorted, filed and submitted in the **exact order as indicated below**.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and may not be considered for evaluation.

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
1	CL	Covering Letter				
2	BSRA	Bid Signature. Resolution/Authority to sign bid				
3	BF1	Bid/File Index				
4	PBD4.1	PBD 4.1: Contact Details of Bidder				
5	SBD5.1	SBD 1: Invitation to bid				
6	TCP	Tax Clearance Pin Issued				
7	CSD	CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted.				
8	SBD4	SBD 4: Declaration of interest				
9	PBD9	PBD9: Directors: Categorisation by race, gender and disability				
10	SBD5	SBD5: The National Industrial Participation Programme				
11	SBD6	SBD 6(1): Preference Points Claimed (B-BBEE)				
12	BBBEE	Valid B-BBEE certificate (certified copy of the original) to claim preference points				
13	EME	Sworn Affidavit (certified copy of the original sworn affidavit), if you are an Exempted Micro Enterprise (see Annexure B attached)				



Special Requirements and Conditions of Contract: HP04-2022ONC

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
14	QSE	Sworn Affidavit (certified copy of the original sworn affidavit), if you are an Qualified Small Enterprise (see Annexure C attached)				
15	HTC	Guide on how to complete EME and QSE sworn affidavit (see Annexure D)				
16	SBD8	SBD 8: Declaration of Past SCM Practices				
17	SBD9	SBD 9: Certificate of Independent Bid Determination				
18	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.				
19	PBD1.1	PBD 1.1: List of products offered sourced from third party				
20	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party.				
21	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.				
22	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.				
23	CIPC	CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates				
24	NC	Proof of company cedings, mergers, acquisition and name changes				
25	LICMI	Licence to manufacture or import (in the name of the bidder), <u>including all annexures. Certified copies required.</u>				
26	LICM	Licence to manufacture or import, including all annexures <u>for local manufacturing sites</u> as listed on the MRC of the bidder (applicant). Certified copies required.				
27	LICMDL	Licence to manufacture/distribute/wholesale medical devices, including all annexures. Certified copies required. (if applicable).				



Special Requirements and Conditions of Contract: HP04-2022ONC

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
28	MRC	Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.				
29	PI	Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order.				
30	PS	Proof of sample submission				
31	BL	Bidder's item list (List of products offered)				
32	PRICE	Signed Excel Bid Response Pricing Schedule If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.				
All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above						
Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column						

The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and be submitted in hard copy and as part of the electronic copies of **"Set 3: Electronic version of bid documents"**



SECTION A

1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract (SRCC) are supplementary to General Conditions of Contract (GCC). Where, however, the SRCC are in conflict with the GCC, the SRCC prevail.

2. BID INFORMATION SESSION

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, a non-compulsory online briefing session will be held via a Zoom Webinar on the 27th of August 2021 at 10H00.

Bidders who wish to partake are required to register on Zoom Webinar not later than Thursday, close of business, 26th of August 2021, by using the following link.

https://health-za.zoom.us/webinar/register/WN_o4ViZZNaThGudla8Zd0BbQ

Upon successful registration you will receive an email detailing your Meeting ID and password to access the Webinar.

It is strongly **recommended** that all prospective bidders submit all enquiries, including possible problems being experienced with the registration process to tenders@health.gov.za. Prospective bidders must submit all enquiries on time to allow the response to reach the bidders before the tender closes.



3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

Phase I	Phase II	Phase III	Phase IV
Mandatory and other bid requirements	Product technical compliance	Price and B-BBEE	Recommendation and Award
Compliance with mandatory and other bid requirements	Compliance with technical specifications Test reports received from sample evaluation	Bids evaluated in terms of the 90/10 preference system	Recommendation and award

3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

A certified copy of the original Medicine Registration Certificate, issued in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), must be included with the bid for all items offered.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965)



including all annexures. A **certified copy** of the original licence must be submitted by the bidder offering the product.

The bidder offering a product must submit a **certified copy** of the original **licence** to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.

Where an item offered is not eligible for registration in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), a package insert of the item must be supplied.

Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.

3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response.

All prices must be submitted with 2 (two) decimals. Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The excel bid response documents i.e. pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof. All pages must be signed.



The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery.

All prices must be submitted with two (2) decimals.

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.

Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.

3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.

In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.

Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration. Where the information is found to be false or incorrect, the National Department of Health reserves the right to exercise any of the remedies available at its discretion.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, may invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

3.1.5 TAX COMPLIANCE STATUS

The Central Supplier Database and the tax compliance status PIN are the approved methods of verifying the tax compliance status of a bidder. The South African Revenue Service does not issue Tax Clearance



Special Requirements and Conditions of Contract: HP04-2022ONC

Certificates anymore but has introduced an online provision via eFiling, for bidders to print their own Tax Clearance Certificates which they can submit with their bids or price quotations.

It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.

It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.

Bidders are required to be registered on the **Government's Central Supplier Database** and to include in their bid **their Master Registration Number (Supplier Number)** in order to enable the institution to verify the supplier's tax status on the Central Supplier Database;.

Foreign suppliers with neither South African tax obligations nor history of doing business in South Africa must complete the questionnaire on the SBD1. Where a recommendation for award of a bid has been made to a foreign bidder, the NDOH will submit the bidder's completed SBD1 to the South African Revenue Service to email address: GovernmentInstitute@sars.gov.za. The South African Revenue Service will issue a confirmation of tax obligations letter to the NDOH, confirming whether or not the foreign entity has tax obligations in South Africa.

Should the recommended bidder fail to provide written proof of their tax compliance status, the NDOH will reject the bid submitted by the bidder.

The National Department of Health shall verify the bidder's tax compliance status through the CSD.

Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database. Bidders remain responsible to update their CSD information in line with the bid documents submitted for this bid.



4. PHASE II: PRODUCT TECHNICAL COMPLIANCE

4.1 SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with the products they are bidding for, to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health establishments listed below may invalidate the bid for such items offered.

Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:

Ms Pretty Nyokong Contract Manager Tel: 011 628 9131 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001
--	---

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.
- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above. Proof of sample submission must be submitted with the bid documents at the closing date and time of the bid
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.



- A mock sample (for example, an empty blister / pack and / artwork) may be submitted for Schedule 6 items (if applicable).
- A mock sample may or may not be accepted for any other item excluding Schedule 6 at the discretion of the National Department of Health.
- All samples submitted must include an eligible package insert or document detailing professional information approved by the MCC or SAHPRA.
- Both Health establishments will evaluate the samples and agree on compliance to the specification.

4.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.

The Department reserves the right to award a product with a Specification Deviation.

5. PHASE IV: PREFERENCE POINT SYSTEM

5.1 A MAXIMUM OF 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

In terms of regulation 6 of the Preferential Procurement Regulations pertaining to the Preferential Procurement Policy Framework Act, 2000 (Act 5 of 2000), responsive bids will be adjudicated by the NDoH on the 90/10-preference point system in terms of which points are awarded to bidders on the basis of:

- The bid price (maximum 90 points)
- B-BBEE status level of contributor (maximum 10 points)



The following formula will be used to calculate the points for price:

$$P_s = 90 \times \left(1 - \frac{P_t - P_{\min}}{P_{\min}} \right)$$

Where:

P_s = Points scored for comparative price of bid under consideration

P_t = Comparative price of bid under consideration

P_{\min} = Comparative price of lowest acceptable bid

5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)
1	10
2	9
3	6
4	5
5	4
6	3
7	2
8	1
Non-compliant contributor	0

- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of the original B-BBEE status level verification certificate, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The original certified copy of the B-BBEE status level certificate must be issued by a SANAS accredited agency.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.



- Exempted Micro Enterprises (EME's) and Qualifying Small Enterprises (QSE's) must submit a Sworn Affidavit as prescribed by the B-BBEE Commission, Practice Guide 01 of 2019.
- Sworn Affidavits submitted by EME's and QSE will strictly be evaluated according to the guidelines as prescribed by the B-BBEE Commission.
- If the bidder fails to comply with the paragraphs above, the bidder may be deemed not to have claimed preference points for B-BBEE status level of contribution and may therefore be allocated a zero (0). The National Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it has made with regard to preference claimed.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.
- The point scored will be rounded off to the nearest two (2) decimals. In the event two (2) or more bids scored equal or total points the contract will be awarded to the bidder scoring the highest number of preference points of B-BBEE.

6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured.

In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture medicines (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.

Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not **negatively impact upon security of supply and affordability**.

Bids for products that qualify for this preference must comply with all of the following criteria:

- The MRC issued by the MCC or SAHPRA lists the primary site of production as one that is located in the Republic of South Africa;



- The site/s of manufacture and/or packaging for the product offered is/are located in the Republic of South Africa;
- The reference price has not been exceeded (if applicable);
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance;
- Compliance to all other aspects contained in the SRCC.

7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the **exact compilation sequence** as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- Status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature;
- Resolution/Authority to sign bid;
- Bid/File Index;
- PBD 4.1: Contact Details of Bidder;
- SBD 1: Invitation to bid;
- Tax Clearance Pin Issued;
- CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted;



Special Requirements and Conditions of Contract: HP04-2022ONC

- SBD 4: Declaration of interest;
- PBD9: Directors: Categorisation by race, gender and disability;
- SBD5: The National Industrial Participation Programme;
- SBD 6(1): Preference Points Claimed (B-BBEE);
- Valid B-BBEE certificate (certified copy) to claim preference points;
- Sworn Affidavit (**certified copy of the original sworn affidavit**), if you are an Exempted Micro Enterprise;
- Sworn Affidavit (**certified copy of the original sworn affidavit**), if you are a Qualified Small Enterprise;
- Guide on how to complete EME and QSE sworn affidavit;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;
- PBD 1.2: Unconditional written undertaking from the third party;
- PBD 5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers, acquisition and name changes;
- Certified copy of Licence to manufacture or import (in the name of the bidder), including all annexures;
- Certified copy of Licence to manufacture medicines, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant);
- Certified copy of Licence to manufacture/distribute/wholesale medical devices, including all annexures. Certified copies required. (if applicable)
- Certified copies of Medicine Registration Certificates (MRC) with all the associated conditions of registration (Annexure). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI's must be marked with the relevant item number and be sorted and filed/submitted in numerical order;



- Proof of sample submission;
- Bidder's item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals). If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation

9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD/ Universal Serial Bus (USB Flashdrive) with Set 1 and submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

Set 1: Hard copy legally binding bid documents

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages. All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, a non-compulsory online briefing session will be held via Zoom (Webinar) on the 27th of August 2021 at 10H00.

Furthermore, Bidders must still ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration.



Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the **price quoted** for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

10. LATE BIDS

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, be returned unopened to the bidder.

11. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

12. FRONTING

The National Department of Health supports the spirit of broad based black economic empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the



accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.

13. SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due diligence prior to final award or at any time during the contract period, involving such steps as the Department may in its entire and absolute discretion deem necessary in order to satisfy itself as to, inter alia, the legal, compliance, financial and operational status and condition of such Bidder, Supplier and/or its Affiliates (as the case may be). This may include site visits to assess whether:

- an item is manufactured at the site specified in the bid documentation;
- the bidder/contracted supplier has two (2) months buffer stock on hand;
- the bidder/contracted supplier has capacity for their allocation or agreed demand.

14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary. Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged.

All communication between the bidder and the National Department of Health, must be done in writing.



15. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines

Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines

Dr AB Xuma Building

1112 Voortrekker Road, Block A

Pretoria Townlands 351-JR

PRETORIA

0187

Please use the following e-mail address for any queries relating to bidding process:

- tenders@health.gov.za



SECTION B

16. CONTRACT PERIOD

The contract shall be for the period ending 30 June 2024.

17. PARTICIPATING AUTHORITIES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are National Departments:

- Department of Correctional Services;
- South African Military Health Services

Provincial Departments:

- | | |
|------------------|---------------------|
| • Eastern Cape; | • Mpumalanga; |
| • Free State; | • Northern Cape; |
| • Gauteng; | • North West; |
| • KwaZulu-Natal; | • Western Cape; and |
| • Limpopo. | |

Other Institutions:

- Nelson Mandela Children's Hospital

18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in the inability to process payment for goods.



19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.

The National Department of Health reserves the right to negotiate prices.

The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The National Department of Health reserves the right to award to an item with a specification deviation.

In the case of medicines for chronic conditions, pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day or other pack size be offered, no conversion factor will be applied. Direct comparisons will be made between the 28-day and other pack sizes during evaluation. Similarly, no conversion factors will be applied in cases where a pack size other than that specified is offered.

The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand.

The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.



20.1 SPLIT AND MULTIPLE AWARDS

The National Department of Health reserves the right to issue split or multiple awards, where necessary, to ensure security of supply.

The following will be taken into consideration when contemplating a split award:

- Source of API and manufacturing site.
- Capacity to meet expected demand as per published estimates in the Bid Response Document.
- Estimated volume to be supplied.
- Risk to public health if the item is not available.
- Past compliance of the bidder with contractual obligations.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

Category	Difference between points scored	Recommended percentage split
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10

Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score - mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%

20.2 THERAPEUTIC CLASS AWARDS

The Policy for Classifying Medicines into Therapeutic Classes for Purposes of Therapeutic Interchange defines a therapeutic class as a group of medicines which have active ingredients with comparable therapeutic effects. Medicines in a therapeutic class may or may not belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may possess different mechanisms of action, result in different adverse reactions, have different toxicity and drug interaction profiles. In most cases,



these medicines have close similarity in efficacy and safety profiles, when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) formulates and revises the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML). Therapeutic classes are mentioned in the "Medicine treatment" section of the national STGs which provides a class of medicines followed by an example such as, HMGCoA reductase inhibitors (Statins) e.g. simvastatin. These therapeutic classes have been designated where none of the members of the class offer any significant benefit over member of the class for a specific indication. The NEMLC will designate therapeutic classes for a condition, where appropriate.

Such therapeutic classes may be used during the contracting process to achieve the most economically advantageous contract, offer the market the largest volume and increase the number of competitors, thereby offering the opportunity for cost efficiencies by stimulating robust competition.

A single member of the class may be awarded.

Therapeutic Class	Therapeutic class description	Members of the therapeutic class
Class 1	Gonadotrophin-releasing hormone (GnRH) analogue	Buserelin 9,9mg, injectable depot implant, single disposable applicator (Item 9) VS Goserelin 10.8mg injection (Item 52)
Class 2	5HT3 Antagonist- Oral	Granisetron 1mg tablet, 10 tablets (Item 55) VS Ondansetron 8mg tablet, 10 tablets (Item 90)
Class 3	Bisphosphonates	Ibandronic acid 6mg injection (Item 58) VS Zoledronic acid 4mg injection (Item 114)
Class 4	Aromatase Inhibitors	Anastrozole 1mg tablet, 28 tablets (Item 1) VS Letrozole 2.5mg tablet, 28 tablets (Item 69)



21 NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full.

The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award

In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.

23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and
- A systematic review of prices for comparable products available in the international market place.

23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on:

The submission of a complete price breakdown per instructions below for all relevant products; and
Assessment of the rationality of this price breakdown by the National Department of Health.

23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components
 - Active Pharmaceutical Ingredients (API);



- Formulation;
- Packaging;
- Logistics (this includes transportation, warehousing and distribution);
- Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.

Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE.

Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

Currency	Base Average Rates of Exchange Average for the period 1 February 2021 to 31 July 2021
Rand per US Dollar	R14.45
Rand per Br Pound	R20.10
Rand per Euro	R17.33



Special Requirements and Conditions of Contract: HP04-2022ONC

Currency	Base Average Rates of Exchange Average for the period 1 February 2021 to 31 July 2021
Rand per Yuan Renminbi	R2.23
Rand per Indian Rupee	R0.20
Rand per Danish Krone	R2.33

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 February 2021 to 31 July 2021 using the South African Reserve Bank published rates for the specific currency.

23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.

Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.

Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.

23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 July 2022 - 31 December 2022	03 January 2023	01 February 2023
2	01 December 2022 – 31 May 2023	03 June 2023	01 July 2023
3	01 July 2023- 31 December 2023	03 January 2024	01 February 2024

23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.



Special Requirements and Conditions of Contract: HP04-2022ONC

Review	Period for calculating adjustment average RoE	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
0.1	01 July 2022 – 30 September 2022	03 October 2022	01 November 2022
1.1	01 January 2023 - 31 March 2023	03 April 2023	01 May 2023
2.1	01 July 2023 – 30 September 2023	03 October 2023	01 November 2023
3.1	01 January 2024 - 31 March 2024	03 April 2024	01 May 2024

Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:

Review	Period for calculating adjustment average RoE post exceptional adjustment	Submission of request for price review to reach the office by	Date from which adjusted prices will become effective
1	01 October 2022 - 31 December 2022	03 January 2023	01 February 2023
2	01 March 2023– 31 May 2023	03 June 2023	01 July 2023
3	01 October 2023 - 31 December 2023	03 January 2024	01 February 2024

23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.

Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.



24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.

25. DELIVERY AND QUANTITIES

25.1 DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.

Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time may result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

25.2 QUANTITIES

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period. Fluctuations in monthly demand may occur.

Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.

Allowances for a reduced yet appropriate buffer stock will be made for the last two (2) months of the contract, as agreed upon between the NDoH and the contracted supplier.



SECTION C

26. SUPPLIER PERFORMANCE MANAGEMENT

26.1 Supplier performance management will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, National Treasury: Transversal Contracting Chief Directorate and National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
 - All transactional data relating to orders;
 - A monthly age analysis;
 - Production pipeline data and forecast including:
 - Number of units of the item available (stock on hand);
 - Number of units of the item in Quality Assurance, awaiting release;
 - Number of units of the item in the current month's production plan.
 - Status of outstanding orders.
- **Attendance of compulsory quarterly meetings**
 - The National Department of Health will hold quarterly meetings with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.
- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.
- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.



Special Requirements and Conditions of Contract: HP04-2022ONC

- Contractors should note that each individual purchasing institution is responsible for generating the order(s) as well as for the payment(s) thereof.
- Contractors should note that the order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s).
- The instructions appearing on the official order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
- The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
- In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
- Only orders made using an official, authorised purchase order format are valid.
- Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
- In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.
- Invoices must reflect both the "proprietary name" (brand name/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.



- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery point. These documents must be delivered to the authority responsible for payment. This may or may not be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where documents must be delivered.
- The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
- Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
- Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contractors must maintain sufficient buffer stock throughout the duration of the contract.
- Contractors must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
 - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
 - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
 - industrial action
 - challenges with manufacturing pipeline;
 - any other supply challenges.
- Contractors must direct official communication relating to continuity of supply to stockalert@health.gov.za, as well as Participating Authorities.
- Contractors must direct official communication relating to payment challenges to medacc@health.gov.za, as well as Participating Authorities.
- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.



Special Requirements and Conditions of Contract: HP04-2022ONC

- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier is required to source alternative product of acceptable quality and up to the same quantity as required for a period of not more than three months. In the case of a multiple award, the alternative product should not be sourced from another contracted supplier for the same product.
- In the event that a contracted supplier is unable to supply in the short term, the National Department of Health reserves the right to proportionally reallocate volumes to an alternative contracted supplier for the duration of the contracted supplier's inability to supply.
- Prior to the supply of an alternative product can be undertaken, the contracted supplier is required to submit the samples of the product to be supplied to the two health establishments as listed in section 4. The contracted supplier is also required to furnish the Department of Health with the following information:
 - Name of the product to be supplied;
 - The quantities to be supplied; and
 - The period for which the product will be supplied.
 - The alternative product must be supplied at the current price of the contracted item.
 - This provision is only applicable for emergency supply and cannot be used for routine and continuous supply of the product.
 - Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
 - In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.



27. PACKAGING, LABELLING AND BARCODES

27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
 - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
 - Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
 - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
 - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;.
 - The outer packaging must be clearly marked as a "Part Box".

27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.



- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
 - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC.
 - Registered product name (if applicable);
 - Number of units in pack
 - Batch number;
 - Expiry date;
 - Storage conditions;
 - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
 - Item name as contained in the contract circular, and the Master Health Products List (MHPL) previously know as the MPC.
 - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
 - Dosage form and strength;
 - Pack size;
 - Batch number;
 - Expiry date.



28 SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
 - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
 - Applications are approved by the Participating Authorities before execution of orders; and
 - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
 - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:
 - $A = (12 - \text{months to date of expiry}) \times 2\% \times \text{consignment value short dated product}$. Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

29. ACQUISITIONS ,CEDING, MERGERS, TAKE OVERS, AND NAME CHANGES

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

Where a contracted supplier plans to cede a contracted item to another supplier, the contracted supplier must submit an official request in writing to the NDOH, three months prior to the proposed effective date.

The NDOH reserves the right to accept or decline the request to cede the contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.



Special Requirements and Conditions of Contract: HP04-2022ONC

The contracted supplier is obliged to supply the contracted item under the prevailing conditions of contract, until such time that the NDOH has approved the request to cede the item to another supplier.

The contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

The National Department of Health reserves the right to agree to the transfer of contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.

A contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

30. CANCELLATION OF THE CONTRACT

Cancellation of a contract will only be considered after compelling evidence to support the request has been submitted to the satisfaction of the Department of Health.

The contracted supplier is obliged to supply the contracted item under the prevailing conditions of contract, until such time that the NDOH has approved the request to cancel the item.

31. THIRD PARTIES

Participating Authorities will not make a payment to or consult with a third party.

No third party is entitled to put an account of a Participating Authority on hold.

END